NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
4.00
Dollar change
+0.11
Percentage change
2.83
%
Index- P/E- EPS (ttm)-0.98 Insider Own30.86% Shs Outstand68.17M Perf Week7.24%
Market Cap308.46M Forward P/E- EPS next Y-0.65 Insider Trans0.00% Shs Float53.32M Perf Month5.26%
Enterprise Value265.40M PEG- EPS next Q-0.13 Inst Own28.91% Short Float14.89% Perf Quarter18.34%
Income-41.40M P/S- EPS this Y62.75% Inst Trans-5.40% Short Ratio6.80 Perf Half Y-18.37%
Sales0.00M P/B5.53 EPS next Y-71.49% ROA-83.20% Short Interest7.94M Perf YTD-25.23%
Book/sh0.72 P/C6.98 EPS next 5Y14.69% ROE-100.13% 52W High10.00 -60.00% Perf Year123.46%
Cash/sh0.57 P/FCF- EPS past 3/5Y0.38% 8.47% ROIC-82.54% 52W Low1.75 128.57% Perf 3Y263.64%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility10.86% 8.21% Perf 5Y36.52%
Dividend TTM- EV/Sales- EPS Y/Y TTM-25.32% Oper. Margin- ATR (14)0.32 Perf 10Y-
Dividend Ex-Date- Quick Ratio4.90 Sales Y/Y TTM- Profit Margin- RSI (14)50.71 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio4.90 EPS Q/Q-13.67% SMA20-1.62% Beta0.57 Target Price15.20
Payout- Debt/Eq0.02 Sales Q/Q- SMA505.63% Rel Volume0.83 Prev Close3.89
Employees31 LT Debt/Eq0.02 EarningsMay 08 AMC SMA200-24.55% Avg Volume1.17M Price4.00
IPOMar 23, 2016 Option/ShortYes / Yes EPS/Sales Surpr.-8.33% - Trades Volume970,870 Change2.83%
Date Action Analyst Rating Change Price Target Change
Jan-02-25Initiated H.C. Wainwright Buy $11
Aug-18-23Initiated Oppenheimer Outperform $7
Dec-01-21Resumed Jefferies Buy $8
May-27-21Initiated Cantor Fitzgerald Overweight $10
Feb-10-21Downgrade Mizuho Buy → Neutral $7 → $4
Sep-12-19Initiated Mizuho Buy
May-29-19Initiated ROTH Capital Buy $6
Aug-24-17Upgrade Credit Suisse Underperform → Neutral
May-01-17Downgrade Credit Suisse Neutral → Underperform
Apr-18-16Initiated Guggenheim Buy
Jun-25-25 08:00AM
Jun-11-25 07:00AM
Jun-04-25 07:00AM
May-28-25 04:01PM
May-09-25 08:32AM
03:41AM Loading…
03:41AM
May-08-25 04:39PM
04:02PM
04:01PM
May-07-25 05:35PM
Apr-23-25 04:08PM
Apr-22-25 06:47PM
Apr-09-25 04:01PM
Mar-28-25 09:30AM
09:29AM
10:39AM Loading…
Mar-26-25 10:39AM
03:02AM
Mar-25-25 07:58PM
04:09PM
04:01PM
Mar-20-25 08:00AM
Mar-19-25 04:01PM
Mar-17-25 04:01PM
Mar-12-25 08:00AM
Feb-04-25 08:00AM
Jan-13-25 07:30AM
Jan-07-25 04:01PM
Dec-18-24 01:23PM
07:30AM
06:45AM
04:01PM Loading…
Dec-17-24 04:01PM
Dec-04-24 04:05PM
Nov-14-24 10:01AM
Nov-13-24 02:18AM
Nov-12-24 04:13PM
04:01PM
Nov-09-24 01:40PM
Nov-05-24 04:02PM
Sep-10-24 08:30AM
Sep-03-24 04:05PM
Aug-06-24 04:15PM
04:01PM
Aug-01-24 08:30AM
Jul-31-24 08:30AM
Jul-25-24 08:30AM
May-31-24 10:00AM
May-30-24 04:02PM
May-12-24 03:26PM
May-07-24 05:12PM
11:07AM
06:35AM
03:09AM
May-06-24 08:58PM
04:21PM
04:01PM
May-02-24 04:02PM
08:30AM
Apr-17-24 09:35AM
Apr-09-24 04:01PM
Apr-01-24 09:35AM
Mar-22-24 12:00PM
Mar-21-24 09:48AM
Mar-20-24 06:32AM
Mar-19-24 04:08PM
04:02PM
Mar-13-24 04:02PM
Feb-12-24 09:22AM
08:30AM
Feb-08-24 04:05PM
Feb-06-24 04:05PM
Jan-23-24 05:00PM
Dec-11-23 12:00PM
Dec-09-23 12:00PM
Dec-07-23 09:40AM
Nov-21-23 09:40AM
Nov-08-23 11:56AM
08:43AM
Nov-07-23 04:32PM
04:01PM
Nov-02-23 09:15AM
Nov-01-23 07:31PM
Oct-31-23 04:02PM
Sep-06-23 04:05PM
Aug-30-23 10:01AM
Aug-08-23 04:35PM
04:01PM
Aug-01-23 08:30AM
Jul-06-23 12:59PM
Jun-29-23 07:00AM
Jun-15-23 07:00AM
Jun-04-23 08:10AM
May-31-23 08:30AM
08:11AM
May-26-23 09:40AM
May-17-23 09:00AM
May-12-23 10:04AM
May-10-23 04:06PM
May-08-23 04:11PM
04:01PM
Apr-24-23 08:38AM
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jones William BentonSee RemarksJun 04 '25Option Exercise3.5019,35767,750173,130Jun 06 04:26 PM
MILLER RICHARD A MDPresident and CEOMay 07 '25Option Exercise3.50559,0731,956,7561,136,707May 09 04:09 PM